All Comments by Takaomi Saido

  1. Cholinergic Transmission and Aβ: Boosting M1 Receptors Treats Model
  2. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.
  3. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice.
  4. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide.
  5. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice.
  6. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease.
  7. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits.
  8. Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease.
  9. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity.
  10. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro.
  11. Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice.
  12. Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice.
  13. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
  14. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.
  15. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis.